# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
Chardan Capital analyst Rudy Li initiates coverage on Reviva Pharmaceuticals (NASDAQ: RVPH) with a Buy rating and announces ...